Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 28, 2015 12:52 PM ET


Company Overview of Applied Genetic Technologies Corporation

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber con...

11801 Research Drive

Suite D

Alachua, FL 32615

United States

Founded in 1999

18 Employees





Key Executives for Applied Genetic Technologies Corporation

Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $313.9K
Chief Financial Officer
Age: 58
Total Annual Compensation: $175.0K
Chief Medical Officer and Vice President
Age: 67
Total Annual Compensation: $336.2K
Senior Director of Process Development
Age: 41
Total Annual Compensation: $122.4K
Compensation as of Fiscal Year 2014.

Applied Genetic Technologies Corporation Key Developments

Applied Genetic Technologies Corporation and 4D Molecular Therapeutics Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development

Applied Genetic Technologies Corporation and 4D Molecular Therapeutics (4DMT) announced a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need. As part of the agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors.

Applied Genetic Technologies Corporation Appoints Bruce A. Peacock to its Board of Directors

Applied Genetic Technologies Corporation announced that it has appointed Bruce A. Peacock to the company's Board of Directors. Mr. Peacock most recently served as Chief Business and Finance Officer for Ophthotech, where he was responsible for strategic planning, finance, manufacturing and business development. Previously, he was CEO and a member of the Board of Directors of The Little Clinic, LLC. During his tenure, he secured licensing arrangements with major national grocery retailers, achieved reimbursement from key payers and increased monthly patient traffic three-fold.

Applied Genetic Technologies Corporation Files Investigational New Drug Application for the Treatment of X-Linked Retinoschisis

Applied Genetic Technologies Corporation announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of X-linked retinoschisis (XLRS). Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues that have been specifically engineered for better penetration to the back of the eye. Pending the FDA's acceptance of the IND application, the Company plans to initiate a clinical study evaluating the safety and efficacy of AGTC's proprietary gene therapy for treating XLRS during the second quarter of 2015 and expects to have initial data during the second half of 2015.

Similar Private Companies By Industry

Company Name Region
Trojan Technologies USA, LLC United States
NaniRx Therapeutics, Inc. United States
ChemGenes Corporation United States
Aseptica, Inc. United States
Abraxis BioScience, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Applied Genetic Technologies Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at